Soybean

Diagnostic Skin Testing

For the Skin Prick Test (Percutaneous), a single drop of the 1:10 or 1:20 w/v Soybean extract is applied to the skin (usually the forearm or back). A sterile lancet is used to prick through the drop into the epidermis. The clinician evaluates the site after 15 to 20 minutes. A wheal (raised area) 3mm larger than the negative control is typically considered a positive result.

Intravenous Nutrition (Lipid Emulsion)

For adults requiring parenteral nutrition, the standard dose of soybean-based lipid emulsion is 1 to 2.5 grams per kilogram (g/kg) of body weight per day. The dose should not exceed 60% of the patient's total daily caloric intake. The infusion rate should be slow, typically starting at 0.1 g/minute for the first 15 to 30 minutes to monitor for adverse reactions.

Allergy Testing

Pediatric dosing for skin testing is identical to adult dosing in terms of concentration, though fewer test sites may be used simultaneously to minimize discomfort and the risk of a systemic reaction.

Intravenous Nutrition

In neonates and infants, the starting dose is often lower (0.5 to 1 g/kg/day) and increased gradually based on the infant's ability to clear triglycerides from the blood. The maximum dose is generally capped at 3 to 4 g/kg/day in the pediatric population, provided liver function and triglyceride levels remain within normal limits.

Renal Impairment

No specific dose adjustment is required for Soybean allergenic extracts in renal impairment. However, in patients receiving intravenous soybean oil, those with end-stage renal disease may have impaired lipid clearance. Monitoring of serum triglycerides is essential.

Hepatic Impairment

Soybean-based lipid emulsions should be used with extreme caution in patients with pre-existing liver disease or cholestasis (impaired bile flow). Long-term use of 100% soybean-based lipids has been associated with Parenteral Nutrition-Associated Liver Disease (PNALD). A dose reduction or transition to a mixed-lipid emulsion (containing fish oil or olive oil) may be necessary.

Elderly Patients

Elderly patients should be started at the lower end of the dosing range for intravenous lipids due to a higher prevalence of cardiovascular and hepatic comorbidities. For allergy testing, the skin's reactivity may be diminished in older adults, potentially leading to false-negative results.

Diagnostic Administration

Soybean allergenic extracts are never for self-administration. They must be administered by a trained healthcare professional, such as an allergist or specialized nurse. The patient must remain in the clinic for at least 30 minutes following the test to be monitored for signs of anaphylaxis (a life-threatening allergic reaction).

Intravenous Administration

Intravenous soybean oil is administered via a central or peripheral venous catheter. It is often 'piggybacked' into a TPN solution or administered as a '3-in-1' mixture (admixture). The infusion must use a specific 1.2-micron filter to remove any large lipid globules or precipitates that could cause an embolism (blood vessel blockage).

In the context of diagnostic testing, a missed appointment simply delays the diagnosis. In the context of parenteral nutrition, if a lipid infusion is missed, it should be restarted as soon as possible according to the healthcare provider's schedule. Do not double the infusion rate to catch up, as this can lead to 'fat overload syndrome.'

Allergy Extract Overdose

An overdose of allergenic extract (e.g., injecting too much during an intradermal test) can trigger anaphylactic shock. Symptoms include hives, swelling of the throat, difficulty breathing, and a rapid drop in blood pressure. Treatment requires immediate administration of epinephrine and emergency supportive care.

Lipid Overdose

Overdose of intravenous soybean oil leads to Fat Overload Syndrome. Signs include sudden elevation in triglycerides, fever, hepatosplenomegaly (enlarged liver and spleen), anemia, and clotting disorders. If this occurs, the infusion must be stopped immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer these products without medical guidance.

When Soybean is used for diagnostic skin testing, the most common side effect is localized itching and redness at the site of the test. This is actually the intended reaction in allergic individuals. The itching typically subsides within 1 to 2 hours, though a 'late-phase' reaction involving swelling and tenderness can occur 4 to 8 hours later.

For intravenous soybean oil, common side effects include:

• Nausea and vomiting: Often occurring shortly after the start of the infusion.
• Headache: A dull, aching sensation that may be related to the rate of lipid entry into the bloodstream.
• Increased temperature (Fever): A mild thermogenic response to lipid metabolism.
• Elevated Triglycerides: A temporary increase in blood fats during and immediately after the infusion.

• Dizziness: A feeling of lightheadedness or vertigo during infusion.
• Flushing: A sudden warmth or redness in the face and neck.
• Sweating (Diaphoresis): Unexplained perspiration during administration.
• Sleepiness: A mild sedative effect observed in some patients receiving parenteral nutrition.

• Fat Overload Syndrome: A serious condition where the body cannot clear the soybean lipids fast enough, leading to systemic inflammation.
• Thrombophlebitis: Inflammation of the vein used for the infusion, especially when using peripheral veins.
• Cholestasis: A condition where bile flow from the liver is reduced, potentially leading to jaundice (yellowing of the skin and eyes).

> Warning: Stop the administration of Soybean products and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis: This is the most critical risk associated with soybean extracts. Symptoms include a sudden feeling of doom, swelling of the tongue or throat, wheezing, extreme difficulty breathing, and fainting. This is a medical emergency.
• Severe Chest Pain: May indicate a lipid embolism or a cardiovascular reaction to the infusion.
• Cyanosis: A bluish tint to the lips, skin, or fingernails, indicating a lack of oxygen in the blood.
• Uncontrolled Bleeding: Can occur if the soybean lipids interfere with blood clotting factors (part of fat overload syndrome).
• High Fever and Chills: May indicate a systemic infection (sepsis) related to the IV line or a severe reaction to the lipid emulsion.

Prolonged use of 100% soybean-based lipid emulsions (over weeks or months) can lead to Parenteral Nutrition-Associated Liver Disease (PNALD). This is characterized by steatosis (fatty liver), cholestasis, and potentially cirrhosis (scarring of the liver). Additionally, long-term use can affect the immune system's ability to fight certain bacterial infections due to the high omega-6 fatty acid content, which can be pro-inflammatory in high doses.

No FDA black box warnings for Soybean allergenic extracts.

However, for Intravenous Lipid Emulsions (which contain soybean oil), there is a significant warning regarding Death in Preterm Infants. According to the FDA-approved labeling for products like Intralipid, deaths in preterm infants have been reported in the medical literature following infusion of intravenous fat emulsions. Autopsy findings often show intravascular fat accumulation in the lungs. Preterm and low-birth-weight infants have poor clearance of intravenous fat emulsion and increased free fatty acid plasma levels following fat emulsion infusion.

Report any unusual symptoms or persistent discomfort to your healthcare provider immediately.

Soybean extracts and emulsions are high-risk biological products that must be handled with precision. The most significant risk is hypersensitivity, which can range from a mild rash to fatal anaphylaxis. Patients with a known history of severe allergy to soy or peanuts (due to potential cross-reactivity) must inform their healthcare provider before any testing or nutritional therapy begins.

As noted in the side effects section, soybean-based lipid emulsions carry a critical warning regarding Preterm Infants. The FDA warns that deaths have occurred in premature neonates due to fat accumulation in the lungs. Healthcare providers must strictly adhere to the recommended daily dose and infusion rates in this population. Monitoring of the infant's ability to eliminate the infused fat (via triglyceride checks) is mandatory.

Allergic Reactions and Anaphylaxis

Any administration of Soybean allergenic extract must be performed in a facility equipped with epinephrine injections, oxygen, and airway management tools. Patients should be screened for the use of beta-blockers, as these medications can make anaphylaxis more difficult to treat and can block the effectiveness of epinephrine.

Organ-Specific Risks

• Hepatotoxicity: Long-term soybean lipid infusion is linked to liver injury. Regular liver function tests (LFTs) are required.
• Hyperlipidemia: Patients with pre-existing high cholesterol or triglycerides may experience severe elevations, increasing the risk of pancreatitis (inflammation of the pancreas).
• Nephrotoxicity: While soybean itself is not directly toxic to the kidneys, the fluid volume and electrolyte balance associated with TPN must be carefully managed in renal patients.

Patients receiving Soybean-based therapies require regular laboratory monitoring:

• Serum Triglycerides: To ensure the body is clearing the fats effectively.
• Liver Function Tests (ALT, AST, Bilirubin): To monitor for signs of parenteral nutrition-associated liver disease.
• Complete Blood Count (CBC): To check for changes in white blood cell counts or platelets.
• Electrolytes: To maintain balance during nutritional therapy.

Soybean allergenic extracts for skin testing typically do not affect the ability to drive, provided no systemic reaction occurs. However, if a patient experiences dizziness or drowsiness during a lipid infusion, they should avoid operating heavy machinery or driving until the symptoms have fully resolved.

There are no direct chemical interactions between soybean and alcohol. However, alcohol can exacerbate liver stress and hypertriglyceridemia. Patients on parenteral nutrition are generally advised to avoid alcohol entirely to protect liver function.

Stopping Soybean allergenic extracts does not require a tapering period. However, for patients on long-term parenteral nutrition, soybean lipids should be discontinued gradually while increasing enteral (oral/tube) intake to prevent 'refeeding syndrome' or sudden caloric deficits.

> Important: Discuss all your medical conditions, especially any history of asthma or heart disease, with your healthcare provider before starting Soybean-based treatments.

There are no absolute drug-drug contraindications where Soybean must never be used, but there are combinations that significantly increase risk:

• Soybean Extract and Non-Selective Beta-Blockers (e.g., Propranolol): While not strictly contraindicated, this combination is dangerous. If the patient has an anaphylactic reaction to the soybean extract, the beta-blocker will prevent epinephrine from working effectively, potentially leading to a fatal outcome.

• Anticoagulants (e.g., Warfarin): Soybean oil contains Vitamin K1, which is a natural clotting factor. Large volumes of intravenous soybean oil can antagonize (block) the effects of Warfarin, making the blood more likely to clot. Prothrombin time (PT/INR) must be monitored daily when starting or stopping soybean lipids.
• Immunosuppressants (e.g., Cyclosporine): Some studies suggest that high-dose soybean lipids can alter the metabolism or distribution of certain immunosuppressive drugs. Close monitoring of drug levels is advised.

• Antihistamines (e.g., Loratadine, Diphenhydramine): These drugs will suppress the 'wheal and flare' reaction during a soybean allergy skin test. Patients must typically stop taking antihistamines 3 to 7 days before the test to ensure an accurate result.
• Tricyclic Antidepressants (TCAs): Similar to beta-blockers, TCAs can interfere with the body's response to emergency medications used during an allergic reaction.

• Cross-Reactivity with Peanuts: Many patients allergic to soybean are also allergic to other legumes, particularly peanuts. This is due to the similarity in protein structures (e.g., Gly m 5 in soy and Ara h 1 in peanuts).
• Egg Allergy: Intravenous soybean lipid emulsions use egg phospholipids as an emulsifier. Patients with a severe egg allergy may react to the lipid emulsion itself, not just the soybean component.

• St. John's Wort: May theoretically increase the metabolism of lipid-based components, though clinical significance is low.
• Fish Oil Supplements: While often used together in 'mixed' lipid emulsions, taking high-dose fish oil supplements alongside 100% soybean IV lipids may alter the inflammatory profile of the patient.

• Serum Bilirubin: High levels of lipids in the blood (lipemia) can interfere with the laboratory measurement of bilirubin, leading to falsely elevated or depressed results.
• Hemoglobin/Hematocrit: Lipemia can also interfere with automated blood cell counters, potentially giving inaccurate readings of red blood cell parameters.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are scheduled for allergy testing.

Soybean products must NEVER be used in the following circumstances:

• Severe Hypersensitivity to Soy or Legumes: If a patient has a known history of life-threatening anaphylaxis to soybean, the use of allergenic extracts for skin testing is generally contraindicated unless performed under extreme caution in a research setting.
• Severe Egg Allergy (for IVLE): Because intravenous soybean emulsions contain egg yolk phospholipids, they are absolutely contraindicated in patients with a history of anaphylaxis to eggs.
• Severe Hyperlipidemia: Patients with baseline triglyceride levels above 1,000 mg/dL should not receive soybean lipid emulsions, as this can trigger acute pancreatitis.
• Severe Lipid Nephrosis: A rare kidney condition where the body cannot process fats correctly.

Conditions requiring a careful risk-benefit analysis include:

• Acute Myocardial Infarction (Heart Attack): The stress of lipid metabolism may be inappropriate during the acute phase of a heart attack.
• Sepsis: While nutrition is needed, high-dose soybean lipids may interfere with certain immune functions during overwhelming infection.
• Liver Failure: The risk of PNALD (Parenteral Nutrition-Associated Liver Disease) is significantly higher, and mixed lipids or reduced doses should be considered.
• Pregnancy: While not contraindicated, the risk of a systemic reaction during skin testing must be weighed against the diagnostic benefit.

Patients who are sensitive to Soybean may also show cross-sensitivity to:

• Peanuts
• Green Peas
• Lentils
• Birch Pollen: Some patients with 'Oral Allergy Syndrome' react to soy because of proteins that mimic birch pollen allergens (Gly m 4).

> Important: Your healthcare provider will evaluate your complete medical history and allergy profile before prescribing Soybean extracts or emulsions.

Soybean allergenic extracts are classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It is unknown whether soybean proteins administered via skin test can cause fetal harm. However, if a systemic reaction (anaphylaxis) occurs in the mother, it can cause severe fetal hypoxia (lack of oxygen). Skin testing is generally deferred until after delivery unless the diagnosis is critical for the mother's immediate management. Intravenous soybean lipids are used in pregnancy when nutritional needs cannot be met otherwise, but monitoring for gestational diabetes and hypertriglyceridemia is essential.

It is not known whether the proteins from soybean allergenic extracts pass into breast milk. However, soybean oil is a natural component of many diets and is used in IV form for lactating women requiring TPN. The risk to the nursing infant is considered low, but the mother should be monitored for any localized or systemic reactions that could interfere with breastfeeding.

Soybean allergenic extracts are approved for use in children of all ages for the diagnosis of soy allergy. However, the risk of a systemic reaction may be harder to monitor in very young infants who cannot communicate symptoms. For Intravenous Soybean Oil, the risk in preterm infants is a major concern (see Black Box Warnings). Pediatric patients require frequent monitoring of serum triglycerides and liver function to prevent long-term complications like PNALD.

Clinical studies of soybean extracts did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, elderly patients have thinner skin, which may lead to more frequent false-positive or false-negative results in skin testing. In nutritional support, the elderly have a higher risk of 'fat overload' due to age-related declines in hepatic and renal clearance.

In patients with impaired kidney function, the main concern with soybean-based products is the management of fluid volume and the potential for impaired lipid clearance. There are no specific dose adjustments for the allergenic extract, but IV lipids must be infused with caution, and triglyceride levels should be checked more frequently than in patients with normal renal function.

Soybean-based lipid emulsions are potentially hepatotoxic with long-term use. In patients with pre-existing liver disease (Child-Pugh Class B or C), the use of 100% soybean oil should be minimized. Healthcare providers may opt for 'lipid-sparing' strategies or use alternative emulsions that contain fish oil, which has anti-inflammatory properties that may protect the liver.

> Important: Special populations require individualized medical assessment and frequent laboratory monitoring to ensure safety.

Soybean allergenic extracts act by eliciting an IgE-mediated hypersensitivity response. The extract contains various proteins, most notably Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin), which are the major storage proteins of the soybean. In sensitized individuals, these proteins bind to IgE antibodies on the surface of mast cells and basophils. This binding triggers a signaling cascade involving tyrosine kinases, leading to the release of pre-formed mediators like histamine, leukotrienes, and prostaglandins.

In the context of Lymphocyte Growth Factor and Interferon gamma EPC classifications, certain soybean-derived peptides have been shown in vitro to modulate T-cell proliferation and cytokine production. Specifically, soy isoflavones and peptides can influence the Th1/Th2 balance, though these mechanisms are more relevant to immunological research than routine clinical allergy testing.

The pharmacodynamic effect of a soybean skin test is almost immediate, with the peak 'wheal' appearing within 15 to 20 minutes. The duration of the localized skin reaction is typically 2 to 4 hours. When used intravenously, the pharmacodynamic effect is the provision of essential fatty acids for prostaglandin synthesis and the maintenance of cell membrane fluidity. The onset of action for preventing fatty acid deficiency is several days of continuous infusion.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) / Negligible (Skin Test) |

| Protein Binding | >95% (Lipids bind to albumin and lipoproteins) |

| Half-life | 30 - 60 minutes (Lipid particles) |

| Tmax | End of infusion (Intravenous) / 20 mins (Skin Test) |

| Metabolism | Hepatic and Peripheral (Beta-oxidation) |

| Excretion | Lungs (as CO2) and Renal (as water) |

• Molecular Components: Includes Gly m 1 through Gly m 8 (proteins), phospholipids, and triglycerides.
• Solubility: Proteins are water-soluble; lipid emulsions are oil-in-water dispersions.
• pH: Allergenic extracts are typically buffered to a pH of 6.0 to 8.0 for stability and to minimize injection site pain.

Soybean belongs to the therapeutic class of Allergenic Extracts (for diagnosis/immunotherapy) and Intravenous Nutritional Supplements (for lipid emulsions). It is related to other food-based extracts like Peanut, Egg, and Milk extracts, as well as other lipid sources like Safflower oil and Fish oil.